Julian Baker - Blueprint Medicines Senior Affairs
| BPMC Stock | USD 95.10 0.47 0.50% |
Executive
Julian Baker is Senior Affairs of Blueprint Medicines Corp
| Age | 57 |
| Address | 45 Sidney Street, Cambridge, MA, United States, 02139 |
| Phone | 617 374 7580 |
| Web | https://www.blueprintmedicines.com |
Blueprint Medicines Management Efficiency
The company has return on total asset (ROA) of (0.1497) % which means that it has lost $0.1497 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4966) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Blueprint Medicines' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 613.2 M, whereas Total Assets are forecasted to decline to about 784.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jane Baj | PTC Therapeutics | N/A | |
| Hege SollieZetlmayer | PTC Therapeutics | N/A | |
| Kathryn CPA | Krystal Biotech | 43 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Christine Utter | PTC Therapeutics | 46 | |
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Christine Wilson | Krystal Biotech | N/A | |
| Linda Carter | PTC Therapeutics | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| John Thomas | Krystal Biotech | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| Camille MD | Amylyx Pharmaceuticals | 71 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.15 |
Blueprint Medicines Corp Leadership Team
Elected by the shareholders, the Blueprint Medicines' board of directors comprises two types of representatives: Blueprint Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Blueprint. The board's role is to monitor Blueprint Medicines' management team and ensure that shareholders' interests are well served. Blueprint Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Blueprint Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Landsittel, Interim Principal Accounting and Financial Officer and Sr. Director of Fin. | ||
| Dr MBA, Chief Officer | ||
| Kathryn MBA, CEO President | ||
| Ariel Hurley, Principal Accounting Officer | ||
| Tracey Esq, Chief VP | ||
| Christina Rossi, Chief Commercial Officer | ||
| Michael CPA, Chief Officer | ||
| Kathryn Haviland, Chief Business Officer | ||
| Christopher Murray, Senior Vice President Technical Operations | ||
| Debra DursoBumpus, Chief Officer | ||
| Alexis AM, CoFounder Director | ||
| JD MBA, Ex Chairman | ||
| Jenna Cohen, Director Relations | ||
| Christina MBA, Chief Officer | ||
| Fouad MD, President Development | ||
| Julian Baker, Senior Affairs |
Blueprint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Blueprint Medicines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.38) % | ||||
| Current Valuation | 5.78 B | ||||
| Shares Outstanding | 63.53 M | ||||
| Shares Owned By Insiders | 0.90 % | ||||
| Shares Owned By Institutions | 99.10 % | ||||
| Number Of Shares Shorted | 3.91 M | ||||
| Price To Earning | 7.93 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 6.986 | Quarterly Revenue Growth 1.266 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.